DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aerospan (Flunisolide Hemihydrate Inhalation) - Summary

 
 



AEROSPAN SUMMARY

AEROSPAN™
(flunisolide HFA, 80 mcg)
Inhalation Aerosol

Flunisolide hemihydrate, the active component of AEROSPANTM (flunisolide HFA, 80 mcg) Inhalation Aerosol, is a corticosteroid.

AEROSPAN Inhalation Aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older. AEROSPAN Inhalation Aerosol is also indicated for asthma patients requiring oral corticosteroid therapy, where adding AEROSPAN Inhalation Aerosol may reduce or eliminate the need for oral corticosteroids.

AEROSPAN Inhalation Aerosol is NOT indicated for the relief of acute bronchospasm.


See all Aerospan indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Aerospan (Flunisolide Inhalation)

VR475 shown significant benefit in a Phase IIb/III trial for severe asthma
Source: Respiratory / Asthma News From Medical News Today [2014.12.12]
Vectura Group plc has announced the publication in the European Respiratory Journal (ERJ) of a clinical study demonstrating positive results from its Phase IIb/III (Acti-AICS-001) clinical trial...

Asthma
Source: MedicineNet Allergy Specialty [2014.12.12]
Title: Asthma
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 12/12/2014 12:00:00 AM

Bed-sharing toddlers 'more likely to develop asthma in later childhood'
Source: Respiratory / Asthma News From Medical News Today [2014.12.11]
Examining an association between toddlers who share the bed with their parents and risk of asthma later in childhood, researchers suggest that the link is multifactorial.

Raised Asthma Risk Seen for Toddlers Who Share Bed With Parents
Source: MedicineNet Sleep Specialty [2014.12.11]
Title: Raised Asthma Risk Seen for Toddlers Who Share Bed With Parents
Category: Health News
Created: 12/11/2014 12:00:00 AM
Last Editorial Review: 12/11/2014 12:00:00 AM

Asthma data shows no additional clinical efficacy benefits for ICS-treatments with a small particle size
Source: Respiratory / Asthma News From Medical News Today [2014.12.09]
GSK has presented data at the British Thoracic Society (BTS) meeting from a systematic analysis of 25 randomised control studies (RCTs), including a meta-analysis of three key efficacy outcomes...

more news >>

Published Studies Related to Aerospan (Flunisolide Inhalation)

Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: a randomized, double-blind, placebo-controlled trial. [2011.10]
BACKGROUND: Inhaled corticosteroids (ICS) are the preferred long-term therapy for subjects with persistent asthma. However, concerns remain about potential effects of long-term ICS use on growth in children. OBJECTIVE: To determine the effect of 1 year of inhalation therapy with flunisolide hydrofluoroalkane (HFA) on growth velocity and bone maturation in children with mild persistent asthma... CONCLUSIONS: In this study, flunisolide HFA did not suppress growth or bone maturation at the highest approved dose for children with persistent asthma. Copyright (c) 2011 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Intranasal flunisolide treatment in patients with non-allergic rhinitis. [2011.04]
Non-allergic rhinitis (NAR) is a heterogeneous disease, characterized by nasal hyperreactivity and inflammation...

High-dose inhaled flunisolide versus budesonide in the treatment of acute asthma exacerbations in preschool-age children. [2009.04]
The role of inhaled corticosteroids in asthma exacerbation is debated. We compared high doses of nebulized budesonide versus high doses of nebulized flunisolide, in association with a short-acting beta-2-agonist, in the treatment of moderate asthma exacerbation in preschool children... High doses of inhaled flunisolide and budesonide are both effective in the management of moderate asthma exacerbations in pre-school-age children, but the flunisolide therapeutic effect was faster than budesonide.

Strength and endurance of the respiratory and handgrip muscles after the use of flunisolide in normal subjects. [2007.07]
OBJECTIVE: To evaluate the effects of the inhaled flunisolide upon the strength and endurance of the respiratory and peripheral muscles of normal subjects... CONCLUSION: Inhalation of flunisolide by normal subjects for 1 month does not cause any acute or clinically perceived effect in the peripheral or respiratory muscles.

Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats. [2006.01]
Feline bronchial disease is commonly treated with oral glucocorticoids (OGC), which might be contraindicated in cats with certain infectious, endocrine, renal, or cardiac diseases...

more studies >>

Clinical Trials Related to Aerospan (Flunisolide Inhalation)

Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) [Completed]
The objective of this cross-over study is to validate the Preference Module of the EARNS-Q in adult subjects (>=18 years of age) with Seasonal Allergic Rhinitis (SAR) taking beclomethasone dipropionate and beclomethasone dipropionate and flunisolide.

Mentored Patient-Oriented Research Career Development Award [Recruiting]
Asthmatics have inflammation in the large airways (tubes through which air travels in and out of the lungs). The large airways are located in the central lung. New research shows that asthmatics also have inflammation in the small airways. The small airways are located in the peripheral lung (the parts of the lung away from the central lung). Until now, most of the inhaled medications available have been made up of big particles that never reach the peripheral lung. The purpose of this study is to try to measure the level of inflammation in the peripheral lung in asthmatics and see if this inflammation can be decreased with different types of inhaled corticosteroids. The investigators will check airway inflammation before and after use of an inhaled corticosteroid that has a large particle size and should only reach the large airways (Flunisolide-CFC), and before and after use of an inhaled, small particle corticosteroid that should reach both the large and small airways (Flunisolide-HFA). Subjects will make 6 study visits over two phases of the study. In the first phase, the investigators will collect baseline information about subjects while they are using placebo (inactive substance). In the second phase, subjects will take either the large or small particle corticosteroid. Visits will involve questionnaires and various tests measuring lung function (such as spirometry, forced oscillation, and methacholine challenge). Exhaled nitric oxide will be measured as an indication of inflammation. Subjects will also measure and make note of lung function at home twice daily using a peak expiratory flow meter. Two of the visits will involve fiberoptic bronchoscopy so that the investigators may collect cells and tissue samples without surgery. Another two of the visits will involve the use of high resolution computed tomography (HRCT) scans to indirectly evaluate disease in distant parts of the lungs.

more trials >>


Page last updated: 2014-12-12

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014